Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
UBE3A
REST API REST API
Homo sapiens
UBE3A is differentially expressed in 343 experiments: 158 organism parts: bone marrow, liver, ... (156 more);, 276 disease states: normal, control, ... (274 more);, 102 cell types 475 cell lines 47 compound treatments and 78 other conditions.
Synonyms ANCR, HPVE6A, AS, EPVE6AP, FLJ26981, E6-AP
Orthologs ube3a (Danio rerio)   Ube3a (Mus musculus)   UBE3A (Gallus gallus)   Ube3a (Rattus norvegicus)   ENSCING00000007494 (Ciona intestinalis)   A4IFN7_BOVIN (Bos taurus)   HUL4 (Saccharomyces cerevisiae)   Ube3a (Drosophila melanogaster)   ube3a (Xenopus laevis)   UBE3A (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, ligase activity, proteasome complex, protein binding, acid-amino acid ligase activity, intracellular, protein ubiquitination, protein ubiquitination involved in ubiquitin-dependent protein catabolic process, positive regulation of transcription from RNA polymerase II promoter, protein modification process, transcription coactivator activity, nucleus, ubiquitin-protein ligase activity, proteolysis, brain development, ubiquitin-dependent protein catabolic process, androgen receptor signaling pathway, prostate gland growth, sperm entry, protein K48-linked ubiquitination, ovarian follicle development, interspecies interaction between organisms, positive regulation of phosphatidylinositol 3-kinase cascade
InterPro Term Ubiquitin-protein_ligase_E6-AP, HECT
UniProt Accession Q96GR7, Q05086, Q9H2G0, Q9UBN9, F8W9C2
Gene-Disease Assocation ANGELMAN SYNDROME; AS
Search EB-eye ENSG00000114062
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-1577, E-MEXP-433, ... (37 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (47 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-20081, E-GEOD-3529, E-GEOD-5823
BT-474
2
E-GEOD-5823, E-GEOD-3529
HCC1143
2
E-MTAB-37, E-MTAB-62
A549
2
E-GEOD-3202, E-GEOD-6013
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
MOLT4
2
E-MTAB-62, E-MTAB-37
469 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, E-GEOD-21909, ... (49 experiments)

Factor Value U/D Experiments
mononuclear
2
E-GEOD-26672, E-GEOD-13987
plasma cell
2
E-MEXP-2360, E-GEOD-6691
2
2
E-TABM-130, E-TABM-145
721 B lymphoblast
2
2
E-AFMX-5, E-TABM-145
memory B cell
2
E-MEXP-2360, E-TABM-702
germ cell
1
E-MTAB-25
96 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-GEOD-16363, ... (79 experiments)

Factor Value U/D Experiments
glioblastoma
1
4
E-GEOD-4290, E-MTAB-62, E-MTAB-37, E-GEOD-4412, E-GEOD-6014 ... (5 experiments)
lung adenocarcinoma
3
E-MTAB-62, E-MTAB-37, E-MEXP-231
acute promyelocytic leukemia
1
3
E-MTAB-62, E-GEOD-1729, E-GEOD-96, E-GEOD-995
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
acute quadriplegic myopathy
2
E-MTAB-62, E-GEOD-3307
dermatomyositis
2
E-MTAB-62, E-GEOD-5370
270 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-1417, E-GEOD-3720, E-GEOD-5824, ... (27 experiments)

Factor Value U/D Experiments
placebo
2
E-MEXP-1327, E-MEXP-1335
TTNPB
1
E-GEOD-5258
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
5-fluorouridine
1
1
E-GEOD-995
saline
1
E-GEOD-3026
sapphyrin PCI-2050
1
E-GEOD-6400
41 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-2171, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-1140, E-MEXP-1251, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-MEXP-2280, E-TABM-147, E-GEOD-21138, E-GEOD-1751, ... (6 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (7 experiments)

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-868, E-MEXP-1838, ... (13 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-GEOD-22278, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-974, E-GEOD-2466, E-MEXP-2069, ... (41 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12254, E-GEOD-9723, E-MEXP-561, ... (7 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-MEXP-1082, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, ... (8 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-22152, E-GEOD-16837, E-GEOD-19246, ... (8 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-GEOD-22541, E-TABM-43, E-GEOD-1561, E-GEOD-4922 ... (5 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.425 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM